Sector News

Stryker Announces Definitive Agreement to Acquire Muka Metal, A.S.

July 22, 2015
Life sciences
Stryker Corporation SYK, +0.69% announced today a definitive agreement to acquire Muka Metal, A.S. (“Muka”) in an all cash transaction. Muka, headquartered in Kayseri, Turkey, sells hospital beds, stretchers and related patient room furniture and accessories that serve markets across Turkey and other regions globally.
 
“The acquisition of Muka aligns with our strategy to expand our global presence through existing channels with an established and trusted brand,” said Timothy J. Scannell, Stryker Group President, MedSurg and Neurotechnology. “This acquisition will bolster Stryker Medical’s bed and stretcher offerings, and is a compelling opportunity to drive growth in Turkey and other regions around the world.”
 
Stryker and Muka have maintained a relationship under a distribution agreement for Latin America since 2012, and with this acquisition Stryker will expand its global presence in key markets with a product portfolio that complements and enhances Stryker’s current offerings.
 
Since launching its first hospital bed in 2002, Muka has established itself as a leading manufacturer and marketer of hospital beds, stretchers and related patient room furniture and accessories. Muka finished construction in mid-2014 of a modern, state of the art facility located in a free trade zone within Kayseri.
 
The closing of the transaction is subject to customary closing conditions. Upon closing, the transaction is expected to be neutral to Stryker’s 2015 earnings per share excluding acquisition, integration-related and intangible amortization charges and accretive thereafter. The transaction is expected to close in the third quarter of 2015.
 
Source: Stryker

comments closed

Related News

January 29, 2023

Colorcon, Inc. signs Put agreement with intent to acquire controlled atmosphere packaging specialist Airnov Healthcare Packaging

Life sciences

Airnov provides critical healthcare industries with high-quality, controlled atmosphere packaging, to protect their products from moisture and oxygen. The business has manufacturing facilities in the USA, France, China and India and employs around 700 people.

January 29, 2023

Takeda pledges up to $1.13B for rights to Hutchmed’s cancer drug fruquintinib outside of China

Life sciences

Takeda of Japan has partnered with Hong Kong-based Hutchmed, gaining the commercial rights to colorectal cancer drug fruquintinib outside of China for $400 million up front, plus $730 million in potential milestone payments. Takeda also will help develop fruquintinib, which can be applied to subtypes of refractory metastatic colorectal cancer, regardless of biomarker status, the companies said.

January 29, 2023

Vir taps Bayer dealmaker Marianne De Backer as its next CEO

Life sciences

On April 3, Scangos, who’s been chief executive officer at Vir since the start of 2017, will hand over the reins to Marianne De Backer, Ph.D. De Backer comes over from Bayer, where she currently heads up pharmaceutical strategy, business development and licensing. Alongside her CEO appointment, De Backer is set to join Vir’s board of directors, the company said Wednesday.

How can we help you?

We're easy to reach